中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

155 records (took 0.015 seconds)

    Interkeukin-1 inhibitor
    12.
    发明授权
    Interkeukin-1 inhibitor 失效
    白介素-1抑制剂

    公开(公告)号：US5359032A

    公开(公告)日：1994-10-25

    申请号：US985506

    申请日：1992-12-01

    Applicant: Jean M. Dayer ,  Philippe L. Seckinger ,  Gonzalo J. Mazzei ,  Alan R. Shaw

    Inventor： Jean M. Dayer ,  Philippe L. Seckinger ,  Gonzalo J. Mazzei ,  Alan R. Shaw

    IPC: A61K38/00 ,  C07K14/47 ,  C07K15/00 ,  A61K37/02

    CPC classification number: C07K14/4703 ,  A61K38/00

    Abstract: This invention relates to interleukin inhibitors (IL-1 INHs) that selectively inhibit interleukin 1 activity. The invention also relates to processes for purifying such IL-1 INHs from urine and for producing such IL-1 INHs by hosts transformed with recombinant DNA molecules comprising DNA sequences encoding the inhibitors, and to methods of treatment and compositions characterized by such IL-1 INHs. These methods and agents are useful in immunosuppressive and anti-inflammatory applications and therapies.

    Abstract translation: 本发明涉及选择性抑制白细胞介素1活性的白介素抑制剂（IL-1 INH）。 本发明还涉及从尿中纯化这种IL-1 INH的方法以及由包含编码该抑制剂的DNA序列的重组DNA分子转化的宿主产生这样的IL-1 INH的方法，以及治疗方法和由这样的IL-1 INHs。 这些方法和试剂可用于免疫抑制和抗炎应用和治疗。

    Method for heat treatment of lactoferrin without losing physiological activities thereof
    13.
    发明授权
    Method for heat treatment of lactoferrin without losing physiological activities thereof 失效
    乳铁蛋白的热处理方法，而不会失去其生理活性

    公开(公告)号：US5340924A

    公开(公告)日：1994-08-23

    申请号：US860224

    申请日：1992-03-27

    Applicant: Mamoru Tomita ,  Yoshitaka Tamura ,  Hiroshi Miyakawa ,  Hitoshi Saito ,  Hiroaki Abe ,  Eiji Nagao

    Inventor： Mamoru Tomita ,  Yoshitaka Tamura ,  Hiroshi Miyakawa ,  Hitoshi Saito ,  Hiroaki Abe ,  Eiji Nagao

    IPC: A23J1/20 ,  A23J3/08 ,  C07K14/79 ,  C07K3/12 ,  C07K15/00 ,  C07K15/14 ,  C07K15/22

    CPC classification number: A23J1/20 ,  A23J3/08 ,  C07K14/79 ,  Y10S530/832

    Abstract: A method for treatment of a matter which contains moisturized or liquified lactoferrin which has been isolated from mammalian milk, processed mammalian milk and by-products in mammalian milk-processing, without losing the physiological activities of lactoferrin, which comprises adjusting pH of said moisturized or liquefied lactoferrin contained in said matter within an acidic range between 2.0 and 6.0 both inclusive by adding acid or aqueous solution of acid when the pH of said moisturized or liquefied lactoferrin is out of said pH range, and heating said matter in the range from 60.degree. C. to 130.degree. C. for a span of time which may assure 60% or more of undenaturization rate of lactoferrin.

    Abstract translation: 一种处理含有保湿或液化的乳铁蛋白的物质的方法，其已从哺乳动物乳，加工的哺乳动物乳和哺乳动物乳加工中的副产物中分离出来，而不损失乳铁蛋白的生理活性，其包括调节所述保湿或 当所述保湿或液化的乳铁蛋白的pH在所述pH范围之外时，通过加入酸或酸的水溶液，在所述物质中含有的液化乳铁蛋白在2.0至6.0之间的酸性范围内，并且将所述物质加热到60℃ 在130℃下，可以确保乳铁蛋白的未饱和化率达到60％以上。

    Peptides derived from human immunodeficiency virus-1 GP160
    14.
    发明授权
    Peptides derived from human immunodeficiency virus-1 GP160 失效
    衍生自人类免疫缺陷病毒-1 GP160的肽

    公开(公告)号：US5338829A

    公开(公告)日：1994-08-16

    申请号：US932078

    申请日：1992-10-19

    Applicant: David B. Weiner ,  Mark I. Greene ,  William V. Williams

    Inventor： David B. Weiner ,  Mark I. Greene ,  William V. Williams

    IPC: A61K38/00 ,  A61K39/00 ,  C07K14/16 ,  C07K14/705 ,  C07K16/10 ,  A61K37/02 ,  C07K3/00 ,  C07K5/00 ,  C07K15/00

    CPC classification number: C07K14/005 ,  C07K14/705 ,  C07K16/1063 ,  A61K38/00 ,  A61K39/00 ,  C12N2740/16122

    Abstract: This invention discloses novel polypeptides having an antigenic determinant or determinants immunologically cross-reactive with determinants of a glycoprotein having a molecular weight of approximately 41,000 daltons, and determinants of a glycoprotein having a molecular weight of approximately 160,000 daltons which are obtained from cells infected with human immunodeficiency virus-1. The invention further discloses novel polypeptides having an antigenic determinant or determinants specific for a glycoprotein having a molecular weight of approximately 41,000 daltons obtained from cells infected with human immunodeficiency virus-1, the polypeptides further having an antigenic determinant or determinants immunologically cross-reactive with at least one glycoprotein having a molecular weight of 25,000 to 35,000 daltons, 45,000 daltons to 60,000 daltons, 80,000 to 100,000 daltons or 180,000 or 220,000 daltons, which are obtained from HSB, St, HeLa and human cells. The novel polypeptides of the invention are useful in methods of interfering with the effects of HIV-1 upon host cells having cell surface polypeptides capable of binding HIV-1. Methods of assay for HIV-1 infection are also disclosed. The invention also discloses peptides having amino acid sequences of about 10 to about 50 amino acids that correspond to at least a portion of an epitope of HIV and methods for developing such biologically active peptides.

    Abstract translation: 本发明公开了具有与具有约41,000道尔顿分子量的糖蛋白的决定簇免疫交叉反应的抗原决定簇或决定簇的新型多肽，以及分子量约为160,000道尔顿的糖蛋白的决定簇，这些糖蛋白是从感染人的细胞获得的 免疫缺陷病毒-1。 本发明进一步公开了具有抗原决定簇或具有特异性的决定簇的新型多肽，该决定簇具有从感染人类免疫缺陷病毒-1的细胞获得的具有约41,000道尔顿的糖蛋白的特异性，所述多肽还具有抗原决定簇或与抗原决定簇免疫交叉反应的决定簇 至少一种由HSB，St，HeLa和人细胞获得的分子量为25,000至35,000道尔顿，45,000道尔顿至60,000道尔顿，80,000至100,000道尔顿或180,000或220,000道尔顿的糖蛋白。 本发明的新型多肽可用于干扰HIV-1对具有能够结合HIV-1的细胞表面多肽的宿主细胞的作用的方法。 还公开了HIV-1感染的测定方法。 本发明还公开了具有对应于HIV表位的至少一部分的约10至约50个氨基酸的氨基酸序列的肽和用于开发此类生物活性肽的方法。

    Colony stimulating factor-gelatin conjugate
    15.
    发明授权
    Colony stimulating factor-gelatin conjugate 失效
    集落刺激因子 - 明胶缀合物

    公开(公告)号：US5298243A

    公开(公告)日：1994-03-29

    申请号：US422701

    申请日：1989-10-17

    Applicant: Yoshito Ikada ,  Yasuhiko Tabata ,  Hiroyasu Suzuki

    Inventor： Yoshito Ikada ,  Yasuhiko Tabata ,  Hiroyasu Suzuki

    IPC: A61K38/19 ,  A61K47/48 ,  C07K15/00 ,  C07K3/02

    CPC classification number: A61K38/193 ,  A61K47/48292

    Abstract: Disclosed are a crosslinked gelatin microspheres containing CSF and a water soluble CSF-gelatin conjugate. Both the microspheres and the water soluble conjugate provide an improved CSF stability. They have a high potentiation on the antitumor activity of macrophages in respect of the CSF amount and the time required for macrophage activation and are effective in maintaining their activated state for a long period, compared with the native CSF. The mechanism of macrophage activation by the microspheres containing CSF is mediated via phagocytosis and different from that by native CSF, which is believed to activate macrophages via cell surface receptor. The species specificity of CSF may be abrogated when the CSF is internalized into macrophages through phagocytosis.

    Abstract translation: 公开了含有CSF和水溶性CSF-明胶缀合物的交联明胶微球。 微球和水溶性缀合物都能提供改善的CSF稳定性。 与天然CSF相比，它们对于巨噬细胞的CSF量和巨噬细胞活化所需的时间对抗巨噬细胞的抗肿瘤活性具有高增强作用，并且与天然CSF相比长效保持其活化状态是有效的。 通过含有CSF的微球的巨噬细胞活化的机制是通过吞噬作用介导的，不同于被认为通过细胞表面受体激活巨噬细胞的天然CSF。 当CSF通过吞噬作用内化于巨噬细胞时，CSF的物种特异性可能被消除。

    Human cytokine
    16.
    发明授权
    Human cytokine 失效
    人类细胞因子

    公开(公告)号：US5278287A

    公开(公告)日：1994-01-11

    申请号：US46243

    申请日：1993-04-13

    Applicant: Barrett Rollins ,  Charles Stiles ,  Gordon G. Wong

    Inventor： Barrett Rollins ,  Charles Stiles ,  Gordon G. Wong

    IPC: C07K14/52 ,  C07K3/00 ,  C07K15/00 ,  C12N5/00 ,  C12P21/06

    CPC classification number: C07K14/523

    Abstract: A novel human cytokine, JE factor, and processes for producing it are disclosed. JE may be used in pharmaceutical preparations for stimulating and/or enhancing immune responsiveness and in wound healing and related tissue repair. containing the factor.

    Abstract translation: 公开了一种新的人细胞因子，JE因子及其制备方法。 JE可以用于药物制剂中，用于刺激和/或增强免疫反应性和伤口愈合和相关组织修复。 含有因子。

    Antigenic compositions and their use for the detection of Helicobacter pylori
    17.
    发明授权
    Antigenic compositions and their use for the detection of Helicobacter pylori 失效
    抗原组成及其用于检测幽门螺杆菌+ B的用途

    公开(公告)号：US5262156A

    公开(公告)日：1993-11-16

    申请号：US744461

    申请日：1991-08-12

    Applicant: Mohammad M. Alemohammad

    Inventor： Mohammad M. Alemohammad

    IPC: C07K14/205 ,  C07K3/00 ,  C07K13/00 ,  C07K15/00 ,  C07K17/00

    CPC classification number: C07K14/205

    Abstract: The invention discloses antigenic compositions and an assay for detecting Helicobacter pylori. The antigenic composition includes a comprehensive mixture of fragments purified from Helicobacter pylori for the detection of Helicobacter pylori infection and/or for monitoring the status of such an infection following treatment. The assay involves an ELISA for urine samples, and includes a kit wherein the antigenic composition is immobilized on a solid support.

    Abstract translation: 本发明公开了抗原组合物和用于检测幽门螺杆菌的测定法。 抗原组合物包括从幽门螺旋杆菌纯化的用于检测幽门螺杆菌感染和/或用于监测治疗后这种感染状况的片段的综合混合物。 该测定涉及尿液样品的ELISA，并且包括其中将抗原组合物固定在固体支持物上的试剂盒。

    Purified insulin mediators and purification process for same
    19.
    发明授权
    Purified insulin mediators and purification process for same 失效
    纯化胰岛素介质和纯化方法

    公开(公告)号：US5122603A

    公开(公告)日：1992-06-16

    申请号：US320484

    申请日：1989-03-08

    Applicant: Joseph Larner ,  Alison Kennington ,  Laura Huang ,  Tsung Y. Shen

    Inventor： Joseph Larner ,  Alison Kennington ,  Laura Huang ,  Tsung Y. Shen

    IPC: G01N33/50 ,  A61K31/70 ,  A61K35/407 ,  A61K49/00 ,  A61P3/08 ,  A61P43/00 ,  C07K1/14 ,  C07K1/16 ,  C07K1/18 ,  C07K1/22 ,  C07K14/00 ,  C07K14/47 ,  G01N30/88 ,  C07K15/00 ,  A01N57/00 ,  C12N9/88

    CPC classification number: C07K14/47 ,  Y10S514/866

    Abstract: A method for purifying two distinct insulin mediators to substantial homogeneity, and relative purity values above 80%, comprises adsorption on first anion exchange resin and subsequently on a chelex cation exchange resin column. The chelex resin ion exchange column substantially increases the activity of the recovered mediator. Following purification, the already treated fraction is subjected to three successive thin layer chromatography purification steps, the last giving, in the presence of ninhydrin stain, a characteristic salmon-color spot, which is indicative of the presence of the mediator. This process can also be used as a screening process, the absence of the salmon-colored spot being indicative of the diabetic state. Structure information on the insulin mediators obtained is given.

    Abstract translation: 一种用于纯化两种不同胰岛素介质以达到基本均匀的方法，并且相对纯度值高于80％的方法包括在第一阴离子交换树脂上吸附，随后在Chelex阳离子交换树脂柱上进行吸附。 衣壳树脂离子交换柱显着增加了回收的介体的活性。 纯化后，已经处理的级分经过三次连续的薄层色谱纯化步骤，最后在茚三酮染色剂存在下给出特征性鲑鱼色斑，这表明存在介体。 该过程也可用作筛选过程，没有鲑鱼色斑点指示糖尿病状态。 给出了获得的胰岛素介质的结构信息。

Patent Agency Ranking